Publications by authors named "Beata Mehes"
Article Synopsis
- - This study assessed the safety, tolerability, and pharmacokinetics of DFV890, an oral NLRP3 inhibitor, in 122 healthy participants through a three-part trial involving single and multiple doses.
- - DFV890 was well-tolerated with no serious adverse events, showing a dose-proportional increase in exposure in the adjusted formulation, while food intake significantly affected its pharmacokinetic profile.
- - The drug effectively inhibited IL-1β release, maintaining about 90% inhibition over 24 hours with specific dosing regimens, suggesting its potential for treating conditions involving NLRP3 overactivation.
Background: Coronavirus-associated acute respiratory distress syndrome (CARDS) has limited effective therapy to date. NLRP3 inflammasome activation induced by SARS-CoV-2 in COVID-19 contributes to cytokine storm.
Methods: This randomised, multinational study enrolled hospitalised patients (18-80 years) with COVID-19-associated pneumonia and impaired respiratory function.